Abstract
Introduction: Anemia, as a common complication of end-stage renal disease (ESRD), usually develops due to erythropoietin deficiency. Recombinant human erythropoietins (rHEPOs) are indicated for the correction of renal anemia. Objectives: We aimed to evaluate the efficacy of a new brand of erythropoietin named CinnaPoietin (erythropoietin beta) on hemoglobin levels. Patients and Methods: This is a randomized double-blinded controlled trial. Ninety-six ESRD patients on hemodialysis recruited in the study, whose hemoglobin levels was less than 10 g/dL. They allocated to two groups. PDPoetin (erythropoietin alfa) 50-100 U/kg three times per week intravenously administrated to the control group and CinnaPoietin with exactly same regimen as like PDPoetin group administrated for the rest of the participants. The study duration was 3 months. We measured plasma hemoglobin monthly for 3 months. Results: We found, hemoglobin was increased across the time and it was statistically significant (P<0.001), while there was no statistically significant differences between the groups (P=0.712). Conclusion: According to the result of the present study there is no statistical significant difference between these two brands of exogenous rHEPO in the case of increasing the hemoglobin concentration.
Highlights
Anemia, as a common complication of end-stage renal disease (ESRD), usually develops due to erythropoietin deficiency
Implication for health policy/practice/research/medical education: In a randomized controlled trial on 96 end-stage renal disease (ESRD) patients on hemodialysis, we found that administration of both brands (CinnaPoietin versus PDPoetin) of recombinant human erythropoietin is effective to increase the hemoglobin concentration in ESRD patients on hemodialysis
We aimed at assessing the efficacy of CinnaPoetin in ESRD patients who were on dialysis in the case of hemoglobin level increase
Summary
As a common complication of end-stage renal disease (ESRD), usually develops due to erythropoietin deficiency. Erythropoiesis-stimulating agents (ESAs) have been available since the early 1980s and it was a great achievement in the management of anemia in dialysis patients [3,4,5]. They are extremely important to maintain hemoglobin level in these patients as it has genteelly affect morbidity as well as quality of life. Solid evidence is available about the equivalence of beta and alfa rHEPOs in the case of efficacy [1,7] Both of them are among the short acting erythropoietin stimulating agents and
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
